Quratis Inc. · 단일판매ㆍ공급계약체결
Single Sales/Supply Contract
| 1. Details of sales/supply contract | Clinical drug product supply contract | |
| 2. Contract details | Conditional contract | Not applicable |
| Confirmed contract amount | 2,489,157,000 | |
| Conditional contract amount | - | |
| Total contract amount (KRW) | 2,489,157,000 | |
| Most recent revenue (KRW) | 2,456,943,982 | |
| Ratio to revenue (%) | 101.31 | |
| 3. Counterparty | Access to Advanced Health (UK) Ltd | |
| - Most recent revenue (KRW) | - | |
| - Main business | Development and distribution of vaccine technology | |
| - Relationship with the company | - | |
| - Similar contracts performed with the company in the last 3 years | Not applicable | |
| 4. Sales/supply region | Location designated by the counterparty | |
| 5. Contract period | Start date | 2026-11-19 |
| End date | 2030-06-30 | |
| 6. Key contract terms | Down payment/advance payment | None |
| Payment terms, etc. | Payment is made when the counterparty accepts the deliverables for each milestone | |
| 7. Sales/supply method | In-house production | Applicable |
| Outsourced production | Not applicable | |
| Other | - | |
| 8. Contract (order) date | 2026-11-19 | |
| 9. Disclosure deferral | Deferral period | - |
| Reason for deferral | - | |
| 10. Other matters to consider for investment decisions | ||
| - The contract amount in 2. Contract details above is the total contract amount of USD 1,870,000 converted at Hana Bank's first published base exchange rate on 2026-11-19 (KRW 1,331.10/USD). - The most recent revenue in 2. Contract details above is based on the separate financial statements for fiscal year 2025. - The counterparty above is a subsidiary of AAHI (Access to Advanced Health Institue) in the United States. It is a new entity established in London, UK in 2025 and has no financial statements available. - Payment terms, etc. under 6. Key contract terms above: . Milestone 1: Contract / technical feasibility (USD 621,000) . Milestone 2: Process development / GMP production (USD 257,400) . Milestone 3: Preliminary stability (USD 102,600) . Milestone 4: CMC documentation (USD 399,000) . Milestone 5: Stability (USD 490,000) | ||
| ※ Related disclosures | - | |